TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Q: What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock, located in New york of Ny and trading under the symbol TARA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TARA Stock Summary

Currently unprofitable, and not expected to turn profitable in the coming year

TARA has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

TARA

Top 10 Correlated Stocks

TARA

In the News

10:56 16 Apr 2024 TARA

Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now

Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

06:00 16 Apr 2024 TARA

3 Stocks That Could Help You Retire on a Private Island

If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can't go the buy-and-hold approach that legendary investors like Warren Buffett deploy. For one thing, that was a different time when the “American Dream” was accessible to any hardworking, industrious individual.

08:00 16 Apr 2024 TARA

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:50 am ET in Boston.

07:30 16 Apr 2024 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:

07:30 16 Apr 2024 TARA

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.

08:00 16 Apr 2024 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

08:00 16 Apr 2024 TARA

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

11:00 16 Apr 2024 TARA

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

07:14 16 Apr 2024 TARA

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

11:17 16 Apr 2024 TARA

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TARA Financial details

Company Rating

Neutral

Market Cap

34.3M

Income

-39.73M

Revenue

Book val./share

6.01

Cash/share

5.77

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-0.4

Forward P/E

-0.75

PEG

0.1

P/S

P/B

0.36

P/C

0.5

P/FCF

-1.02

Quick Ratio

10.93

Current Ratio

11.49

Debt / Equity

0.08

LT Debt / Equity

0.07

EPS (TTM)

-3.51

EPS next Y

-3.83

EPS next Q

EPS this Y

-38.02%

EPS next Y

9.12%

EPS next 5Y

-56.13%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

3.45%

SMA20

-25%

SMA50

SMA100

200%

Inst Own

41.21%

Inst Trans

0.89%

ROA

-77%

ROE

-76%

ROC

-0.15%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.04-5.24

52W High

-42.8%

52W Low

+186%

RSI

Rel Volume

0.51

Avg Volume

229.16K

Volume

117.58K

Perf Week

-16.62%

Perf Month

-23.53%

Perf Quarter

102.12%

Perf Half Y

65.32%

Beta

1.877

Volatility

0.15%, 0.42%

Prev Close

0.7%

Price

2.86

Change

-5.3%

TARA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-228.6	-4.63	-4.2	-5.76	-3.57
Operating cash flow per share	-242.81	-3.24	-3.07	-2.35	-3.31
Free cash flow per share	-243.06	-3.36	-3.12	-2.36	-3.32
Cash per share	95.92	23.31	8.12	7.49	5.79
Book value per share	99.2	27.54	14.41	9.07	6.03
Tangible book value per share	99.2	19.38	9.16	9.07	6.03
Share holders equity per share	99.2	27.54	14.41	9.07	6.03
Interest debt per share	0	0.15	0.8	0.67	0.48
Market cap	1.06M	175.13M	75.82M	30.18M	21.3M
Enterprise value	-5.12M	7.62M	47.33M	12.43M	-12.82M
P/E ratio	-0.07	-5.23	-1.61	-0.47	-0.53
Price to sales ratio	0	0	0	0	0
POCF ratio	-0.07	-7.48	-2.2	-1.14	-0.57
PFCF ratio	-0.07	-7.21	-2.16	-1.14	-0.57
P/B Ratio	0.17	0.88	0.47	0.3	0.31
PTB ratio	0.17	0.88	0.47	0.3	0.31
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0.34	-0.22	-1	-1.55	0.3
EV to operating cash flow	0.33	-0.33	-1.37	-0.47	0.34
EV to free cash flow	0.33	-0.31	-1.35	-0.47	0.34
Earnings yield	-13.94	-0.19	-0.62	-2.15	-1.9
Free cash flow yield	-14.82	-0.14	-0.46	-0.88	-1.77
Debt to equity	0	0.01	0.04	0.06	0.08
Debt to assets	0	0.01	0.04	0.06	0.07
Net debt to EBITDA	0.41	4.89	0.6	2.21	0.79
Current ratio	11.96	58.13	21.66	15.01	11.17
Interest coverage	0	-1.01K	-27.34	-58.98	0
Income quality	1.04	0.69	0.73	0.4	0.93
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0.15	0.17	0	0
Capex to operating cash flow	0	0.04	0.02	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.06	-4.51	-5.09	-0.48	-0.13
Stock based compensation to revenue	0	0	0	0	0
Graham number	714.29	53.58	36.89	34.27	22
ROIC	-2.34	-0.17	-0.27	-0.57	-0.55
Return on tangible assets	-2.11	-0.19	-0.33	-0.57	-0.51
Graham Net	86.88	22.77	7.27	6.58	4.87
Working capital	6.39M	166.52M	88.81M	80.41M	62.56M
Tangible asset value	6.39M	169.73M	132.4M	102.08M	68.32M
Net current asset value	6.39M	165.52M	82.43M	74.94M	58.07M
Invested capital	0	0.01	0.04	0.06	0.08
Average receivables	0	0	317K	560K	364K
Average payables	352K	588.5K	934K	1.27M	2.01M
Average inventory	0	0	607.5K	1.19M	581.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	6K	1.7K	298.38	2.34K	2.61K
Days of inventory on hand	0	0	380.01	1.72K	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.06	0.21	1.22	0.16	0.14
Inventory turnover	0	0	0.96	0.21	0
ROE	-2.3	-0.17	-0.29	-0.63	-0.59
Capex per share	-0.25	-0.12	-0.05	-0.01	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-3.45	-0.74	-1	-0.87	-0.9
Operating cash flow per share	-0.45	-1.14	-0.83	-0.58	-0.77
Free cash flow per share	-0.45	-1.14	-0.83	-0.58	-0.77
Cash per share	7.49	7.66	7.11	6.52	5.77
Book value per share	9.06	8.38	7.54	6.78	6.01
Tangible book value per share	9.06	8.38	7.54	6.78	6.01
Share holders equity per share	9.06	8.38	7.54	6.78	6.01
Interest debt per share	0.58	0.48	0.52	0.5	0.48
Market cap	30.2M	35.38M	27.03M	18.95M	21.37M
Enterprise value	12.45M	20.51M	-1.02M	-9.12M	-12.75M
P/E ratio	-0.19	-1.06	-0.6	-0.48	-0.52
Price to sales ratio	0	0	0	0	0
POCF ratio	-6.01	-2.75	-2.87	-2.89	-2.46
PFCF ratio	-6	-2.74	-2.87	-2.87	-2.46
P/B Ratio	0.3	0.37	0.32	0.25	0.31
PTB ratio	0.3	0.37	0.32	0.25	0.31
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0.64	-2.11	0.08	0.85	1.17
EV to operating cash flow	-2.48	-1.59	0.11	1.39	1.47
EV to free cash flow	-2.47	-1.59	0.11	1.38	1.47
Earnings yield	-1.29	-0.24	-0.42	-0.52	-0.48
Free cash flow yield	-0.17	-0.36	-0.35	-0.35	-0.41
Debt to equity	0.06	0.07	0.07	0.07	0.08
Debt to assets	0.06	0.06	0.06	0.06	0.07
Net debt to EBITDA	-0.91	1.53	2.32	2.62	3.12
Current ratio	15.01	14.76	17.09	11.49	11.17
Interest coverage	191.35	14.17	0	0	0
Income quality	0.13	1.42	0.83	0.67	0.85
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0.01	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0.01	-0.08	-0.03	-0.35	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	26.51	11.81	13.01	11.51	11.03
ROIC	0.18	-0.08	-0.12	-0.12	-0.14
Return on tangible assets	-0.34	-0.08	-0.12	-0.11	-0.13
Graham Net	6.58	6.64	6.41	5.52	4.85
Working capital	80.41M	88.21M	79.33M	71.04M	62.56M
Tangible asset value	102.08M	94.77M	85.23M	76.96M	68.32M
Net current asset value	74.94M	82.98M	74.35M	66.3M	58.07M
Invested capital	0.06	0.07	0.07	0.07	0.08
Average receivables	433K	488.5K	417.5K	311.5K	260.5K
Average payables	1.02M	2.83M	2.97M	2.18M	2.47M
Average inventory	581.5K	336K	1.53M	1.64M	-139.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	1.93K	4.77K	396.86	2.11K	2.05K
Days of inventory on hand	1.41K	-573.9	762.86	-234.67	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.05	0.02	0.23	0.04	0.04
Inventory turnover	0.06	-0.16	0.12	-0.38	0
ROE	-0.38	-0.09	-0.13	-0.13	-0.15
Capex per share	0	0	0	0	0

TARA Frequently Asked Questions

What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA

What is Protara Therapeutics, Inc. stock quote today ?

Protara Therapeutics, Inc. stock price is $2.86 today.

Is Protara Therapeutics, Inc. stock public?

Yes, Protara Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 229.16K
Market Capitalization 34.3M
Employee 26
CEO Mr. Jesse Shefferman
Headquarters New York,NY,US
IPO Date 2014-10-22
Website https://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.